

# Juan-Jesús Cruz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8129006/publications.pdf>

Version: 2024-02-01

121  
papers

2,856  
citations

249298

26  
h-index

232693

48  
g-index

131  
all docs

131  
docs citations

131  
times ranked

4236  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac magnetic resonance to detect different patterns of myocardial injury in patients receiving immune checkpoint inhibitors. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2022, 75, 266-269.	0.4	0
2	Resonancia magnética cardiaca para la detección de diferentes mecanismos de daño miocárdico en pacientes que reciben tratamiento con inmunoterapia. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 266-269.	0.6	0
3	Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. <i>Biomedicines</i> , 2022, 10, 360.	1.4	17
4	Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. <i>Clinical and Translational Oncology</i> , 2021, 23, 764-772.	1.2	13
5	Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications. <i>Biomolecules</i> , 2021, 11, 254.	1.8	28
6	SEOM clinical guidelines for the treatment of head and neck cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 913-921.	1.2	40
7	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC). <i>Journal of Clinical Oncology</i> , 2014, 32, 463-475.	5.1	95
8	Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. <i>Journal of Clinical Medicine</i> , 2021, 10, 1919.	1.0	5
9	Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays. <i>Cancers</i> , 2021, 13, 2718.	1.7	9
10	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , 2021, 22, 727-736.	5.1	45
11	Impacto de un programa de rehabilitación integral funcional en la calidad de vida del paciente oncológico con disnea. <i>Medicina Clínica</i> , 2021, 157, 10-16.	0.3	3
12	Impact of a comprehensive functional rehabilitation programme on the quality of life of the oncological patient with dyspnoea. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 10-16.	0.1	4
13	Autoimmune Responses in Oncology: Causes and Significance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8030.	1.8	12
14	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. <i>JCO Oncology Practice</i> , 2021, 17, e1162-e1169.	1.4	0
15	The Influence of Diet and Probiotics on the Response of Solid Tumours to Immunotherapy: Present and Future Perspectives. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8445.	1.3	2
16	Multimodal physical exercise and functional rehabilitation program in oncological patients with asthenia. study protocol. <i>BMC Nursing</i> , 2021, 20, 207.	0.9	2
17	Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors. <i>Life</i> , 2021, 11, 1400.	1.1	1
18	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. <i>Clinical and Translational Oncology</i> , 2020, 22, 1049-1058.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Effectiveness of an Occupational Therapy Program on Cancer Patients with Dyspnea: Randomized Trial. <i>Physical and Occupational Therapy in Geriatrics</i> , 2020, 38, 43-55.	0.2	4
20	Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109684.	2.5	22
21	Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression. <i>Cancer Research</i> , 2020, 80, 5216-5230.	0.4	17
22	Study of Chemotherapy-Induced Cognitive Impairment in Women with Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8896.	1.2	25
23	Fortalecimiento de la musculatura respiratoria en mujeres mayores en Atención Primaria. <i>Fisioterapia</i> , 2020, 42, 260-266.	0.2	0
24	Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial. <i>Scientific Reports</i> , 2020, 10, 16634.	1.6	12
25	Clinical Perspective and Translational Oncology of Liquid Biopsy. <i>Diagnostics</i> , 2020, 10, 443.	1.3	28
26	Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers. <i>Diagnostics</i> , 2020, 10, 215.	1.3	83
27	Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. <i>Journal of Pain Research</i> , 2019, Volume 12, 2349-2358.	0.8	8
28	Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population. <i>Cancers</i> , 2019, 11, 493.	1.7	15
29	Estudio aleatorizado sobre la influencia de un programa de rehabilitación integral funcional en el control de la astenia relacionada con la enfermedad oncológica. <i>Medicina Paliativa</i> , 2018, 25, 160-167.	0.1	1
30	A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain. <i>Clinical and Translational Oncology</i> , 2018, 20, 1061-1071.	1.2	14
31	Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors. <i>Urology</i> , 2018, 117, 41-43.	0.5	15
32	Oncologists' knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. <i>Clinical and Translational Oncology</i> , 2018, 20, 613-618.	1.2	13
33	SEOM clinical guidelines for the treatment of head and neck cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 75-83.	1.2	27
34	Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate. <i>Annals of Nuclear Medicine</i> , 2018, 32, 568-572.	1.2	8
35	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 0z784314 rgeT /Ov	1.2	14
36	Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. <i>Oncotarget</i> , 2018, 9, 24081-24096.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. <i>Oncotarget</i> , 2018, 9, 36894-36905.	0.8	9
38	Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 451-460.	0.3	11
39	Carcinoma nasofaríngeo familiar en zona no endémica. Presentación de 3 familias. <i>Acta Otorrinolaringológica Española</i> , 2017, 68, 164-168.	0.2	2
40	Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. <i>Frontiers in Neuroendocrinology</i> , 2017, 45, 25-34.	2.5	46
41	A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. <i>Clinical and Translational Oncology</i> , 2017, 19, 1350-1357.	1.2	6
42	Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 491-495.	0.6	0
43	Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer. <i>Breast Journal</i> , 2017, 23, 745-746.	0.4	3
44	Familial Clustering of Nasopharyngeal Carcinoma in Non-Endemic Area. Report of Three Families. <i>Acta Otorrinolaringológica (English Edition)</i> , 2017, 68, 164-168.	0.1	0
45	Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 6887.	1.6	24
46	Management of infection and febrile neutropenia in patients with solid cancer. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed )</i> , 2017, 35, 451-460.	0.2	3
47	Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. <i>Patient Preference and Adherence</i> , 2016, 10, 1.	0.8	16
48	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 553-558.	2.3	7
49	Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. <i>Oral Oncology</i> , 2016, 63, 38-43.	0.8	21
50	Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. <i>Advances in Therapy</i> , 2016, 33, 2059-2068.	1.3	8
51	A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. <i>British Journal of Cancer</i> , 2016, 114, 1191-1198.	2.9	14
52	Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. <i>Oral Oncology</i> , 2016, 62, 54-59.	0.8	14
53	Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location. <i>Clinical and Translational Oncology</i> , 2016, 18, 1114-1122.	1.2	12
54	Management of infection and febrile neutropenia in patients with solid cancer. <i>Clinical and Translational Oncology</i> , 2016, 18, 557-570.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHCN).. Journal of Clinical Oncology, 2016, 34, 6001-6001.	0.8	17
56	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS ONE, 2015, 10, e0132449.	1.1	41
57	Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Molecular and Clinical Oncology, 2015, 3, 725-729.	0.4	5
58	Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach. Genome Biology, 2015, 16, 40.	3.8	23
59	Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients. Clinical and Translational Oncology, 2014, 16, 158-165.	1.2	6
60	A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Annals of Oncology, 2014, 25, 216-225.	0.6	297
61	The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology, 2014, 25, 9-15.	0.6	52
62	Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. Breast Cancer Research and Treatment, 2014, 148, 415-421.	1.1	15
63	Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. Clinical and Translational Oncology, 2014, 16, 914-920.	1.2	6
64	Analysis of DNA repair gene polymorphisms in glioblastoma. Gene, 2014, 536, 79-83.	1.0	31
65	Optimal management of breakthrough cancer pain (BCP). Clinical and Translational Oncology, 2013, 15, 526-534.	1.2	11
66	SEOM Guidelines 2013: a response to the needs of Spanish oncologists. Clinical and Translational Oncology, 2013, 15, 975-976.	1.2	2
67	Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group. Journal of Clinical Oncology, 2013, 31, 2854-2860.	0.8	253
68	SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). Clinical and Translational Oncology, 2013, 15, 20-25.	1.2	6
69	Incidence of $\Delta^{+93}$ MLH1 promoter polymorphism in familial and sporadic colorectal cancer. Colorectal Disease, 2013, 15, e118-e123.	0.7	8
70	<i>C2ORF40</i> suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics, 2013, 8, 571-583.	1.3	42
71	Integrated Analysis of Mismatch Repair System in Malignant Astrocytomas. PLoS ONE, 2013, 8, e76401.	1.1	22
72	Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Annals of Oncology, 2012, 23, 1016-1022.	0.6	196

#	ARTICLE	IF	CITATIONS
73	Soft tissue myoepithelial carcinoma without EWSR1 gene rearrangement and poor outcome. A case report. <i>Revista Espanola De Patologia</i> , 2012, 45, 58-63.	0.6	4
74	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , 2012, 14, 820-826.	1.2	1
75	In answer to: "Comments to SEOM clinical guidelines for the treatment of thyroid cancer" by Garcilaso Riesco-Eizaguirre et al. <i>Clinical and Translational Oncology</i> , 2012, 14, 711-712.	1.2	0
76	Multiple Novel Alternative Splicing Forms of FBXW7 Have a Translational Modulatory Function and Show Specific Alteration in Human Cancer. <i>PLoS ONE</i> , 2012, 7, e49453.	1.1	12
77	Breakthrough cancer pain &ndash; still a challenge. <i>Journal of Pain Research</i> , 2012, 5, 559.	0.8	33
78	Spanish Society of Medical Oncology (SEOM) Cancer and Thrombosis Working Group. <i>Clinical and Translational Oncology</i> , 2012, 14, 160-160.	1.2	0
79	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012, 14, 423-429.	1.2	7
80	SEOM clinical guidelines: a consolidated project. <i>Clinical and Translational Oncology</i> , 2012, 14, 489-490.	1.2	1
81	SEOM clinical guidelines for the treatment of thyroid cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 574-579.	1.2	14
82	SEOM clinical guidelines for the treatment of head and neck cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 742-748.	1.2	8
83	SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 749-752.	1.2	2
84	Cancer as a reprogramming-like disease: Implications in tumor development and treatment. <i>Seminars in Cancer Biology</i> , 2010, 20, 93-97.	4.3	39
85	Interstitial granulomatous dermatitis with arthritis associated with trastuzumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 493-494.	1.3	18
86	Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. <i>British Journal of Cancer</i> , 2010, 102, 1687-1691.	2.9	52
87	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	1.2	3
88	The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease. <i>Stem Cell Reviews and Reports</i> , 2008, 4, 67-79.	5.6	29
89	Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 739-744.	1.2	2
90	New options in the treatment of locally advanced head and neck cancer: Role for induction chemotherapy. <i>Cancer Treatment Reviews</i> , 2008, 34, 268-274.	3.4	17

#	ARTICLE	IF	CITATIONS
91	Third Nerve Palsy as the Initial Presenting Sign of Metastatic Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 407-408.	0.6	3
92	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2656-2663.	0.8	53
93	Reversible Posterior Leukoencephalopathy Syndrome Induced by Sunitinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 3559-3559.	0.8	91
94	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. <i>Annals of Oncology</i> , 2007, 18, 421-430.	0.6	40
95	Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients. <i>Cancer Letters</i> , 2007, 255, 71-76.	3.2	1
96	Tonic Clonic Seizure as the Presentation Symptom of Severe Hypocalcemia Secondary to Zoledronic Acid Administration. <i>Journal of Palliative Medicine</i> , 2007, 10, 1226-1227.	0.6	10
97	BRCA1/2 mutations in breast cancer: Identification of nine new variants of BRCA1/2 genes in a population from central Western Spain. <i>Cancer Letters</i> , 2006, 233, 172-177.	3.2	23
98	Trastuzumab and Antiestrogen Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 90-95.	0.6	31
99	Patient with disseminated intravascular coagulation as the first manifestation of adenocarcinoma of the prostate. Risks of prostatic biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2006, 9, 190-191.	2.0	15
100	CASE 3. Upper Limb Lymphangiosarcoma Following Breast Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1477-1478.	0.8	9
101	Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 77-82.	0.7	5
102	Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. <i>Clinical and Translational Oncology</i> , 2005, 7, 99-100.	1.2	8
103	Neutropenia and enterocolitis with docetaxel treatment. <i>Clinical and Translational Oncology</i> , 2005, 7, 95-95.	1.2	1
104	Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer. <i>Clinical and Translational Oncology</i> , 2005, 7, 358-360.	1.2	17
105	Metastatic prostate cancer with a normal prostate-specific antigen level. <i>Clinical and Translational Oncology</i> , 2005, 7, 412-413.	1.2	5
106	Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. <i>Investigational New Drugs</i> , 2005, 23, 243-251.	1.2	11
107	Evaluation of Multiparameter Flow Cytometry for the Detection of Breast Cancer Tumor Cells in Blood Samples. <i>American Journal of Clinical Pathology</i> , 2005, 123, 66-74.	0.4	76
108	Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study. <i>European Journal of Cancer</i> , 2005, 41, 1254-1260.	1.3	19

#	ARTICLE	IF	CITATIONS
109	Analysis ofBRCA1andBRCA2genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects. <i>Human Mutation</i> , 2003, 22, 301-312.	1.1	154
110	A Multicenter Phase II Study of Irinotecan in Patients with Advanced Colorectal Cancer Previously Treated with 5-Fluorouracil. <i>Clinical Colorectal Cancer</i> , 2003, 3, 174-179.	1.0	3
111	Biweekly Docetaxel and Vinorelbine in Anthracycline-Resistant Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 127-131.	0.6	17
112	Biweekly Docetaxel and Vinorelbine in Anthracycline-Resistant Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 127-131.	0.6	16
113	Î³-Herregulin has no biological significance in primary breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 1362-1363.	2.9	8
114	Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracilwith or without leucovorin, in locally advanced head and neck cancer. <i>Annals of Oncology</i> , 1997, 8, 713-714.	0.6	9
115	Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. <i>Cancer Letters</i> , 1996, 101, 137-142.	3.2	17
116	Mediastinal mass following chemotherapy in patients with Ewing sarcoma and osteosarcoma. <i>Journal of Internal Medicine</i> , 1996, 239, 457-460.	2.7	10
117	Presentation of an acquired factor VIII inhibitor with a muscular haematoma mimicking a deep venous thrombosis in a patient with breast cancer. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, 680-682.	0.5	10
118	A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. <i>Cancer</i> , 1995, 76, 559-563.	2.0	24
119	Neoadjuvant Chemotherapy with Cisplatin and 5-Fluorouracil, Both in Continuous 96-Hour Infusion, in the Treatment of Locally Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 6-9.	0.6	6
120	A Prospective Randomized Trial of Continuous Infusion 5-Fluorouracil (5-FU) Versus 5-FU Plus Cisplatin in Patients with Advanced Colorectal Cancer A Trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992, 15, 56-60.	0.6	14
121	Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. <i>Cancer</i> , 1989, 63, 1927-1930.	2.0	31